Skip to main content

Table 4 The association between evidence-based indication, prescription of renin angiotensin system antagonist and acute kidney injury

From: Acute kidney injury: an acceptable risk of treatment with renin-angiotensin system blockade in primary care?

Indication for ACE/ARB ACE/ARB No AKI AKI
   N (%) N (%)
No No 83,724 (97.8%) 1,846 (2.2%)
  Yes 18,331 (96.2%) 721 (3.8%)
Yes No 25,542 (94.1%) 1,594 (5.9%)
  Yes 72,044 (94.2%) 4,473 (5.8%)
No AKI/AKIN1 versus AKIN2/AKIN3
Indication for ACE/ARB ACE/ARB No AKI/AKIN1 AKIN2/AKIN3
   N (%) N (%)
No No 85,428 (99.83%) 142 (0.17%)
  Yes 18,989 (99.67%) 63 (0.33%)
Yes No 27,032 (99.62%) 104 (0.38%)
  Yes 76,267 (99.67%) 250 (0.33%)
  1. AKI (acute kidney injury), AKIN1 (acute kidney injury network stage 1), AKIN2 (acute kidney injury network stage 2), AKIN3 (acute kidney injury network stage 3), CKD (chronic kidney disease), ACE (angiotensin converting enzyme inhibitor), ARB (angiotensin receptor blocker), IHD (ischaemic heart disease), BP (blood pressure).